Related Experiment Videos
Beta-adrenergic blocker mortality trials in congestive heart failure
1Section of Cardiology, San Francisco Veterans Affairs Medical Center, Cardiovascular Research Institute, University of California San Francisco, 94121-1545, USA.
The American Journal of Cardiology
|November 24, 1999
Summary
Beta-adrenergic blocker therapy is now a standard treatment for congestive heart failure, evolving from a contraindication to a life-saving intervention. Studies show these drugs improve survival by 1 life for every 35 patients treated.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Beta-adrenergic blockers were once contraindicated for patients with congestive heart failure.
- Recent evidence has transformed their role to a cornerstone therapy.
- This evolution is crucial for managing heart failure progression.
Purpose of the Study:
- To review the pivotal studies demonstrating the benefits of beta-blocker therapy in heart failure.
- To discuss major mortality trials and their findings on survival improvement.
- To analyze the impact of beta-blockers on sudden cardiac death in heart failure patients.
Main Methods:
- Review of early studies and major mortality trials involving beta-blockers (metoprolol, bisoprolol, carvedilol, bucindolol).
- Analysis of varying study designs, patient populations, objectives, and limitations.
- Examination of data regarding survival benefits and reduction in sudden death.
Main Results:
- Beta-adrenergic blocker therapy significantly improves survival in patients with congestive heart failure.
- These agents limit the progression of the disease.
- Treatment can save one life for every 35 patients with mild-to-moderate heart failure.
Conclusions:
- Beta-adrenergic blockers are essential for improving outcomes in congestive heart failure.
- The evidence from major trials strongly supports their use.
- Effective titration strategies like "starting low and going slow" are well-established.